Skip to content

AVEIR Remote Care System Non-Significant Risk Study

AVEIR Remote Care System Data Collection Non-Significant Risk Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06542133
Enrollment
32
Registered
2024-08-07
Start date
2024-06-10
Completion date
2024-08-30
Last updated
2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bradycardia, Cardiac Pacemaker, Cardiac Rhythm Disorder

Brief summary

The goal of the study is to understand the performance of the AVEIR Remote Care System in an initial patient cohort which will inform the ability to offer a remote follow-up solution to all patients implanted with Aveir LP devices.

Detailed description

To collect acute performance data about the AVEIR Remote Care System in participants implanted with a compatible dual or single chamber Aveir Leadless Pacemaker System by participants completing remote transmissions with the system

Interventions

DEVICEAVEIR remote care system

In-clinic or an at-home system designed to support remote follow up in Aveir leadless pacemaker patients

Sponsors

Abbott Medical Devices
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject must provide written informed consent prior to any study-related procedure. * Subject is willing and has consented to study clinical procedure. * Subject is ≥ 18 years of age or age of legal consent, whichever age is greater * Subject has an active, appropriately functioning Aveir leadless pacemaker system * Subject is willing to use the device

Exclusion criteria

* Subject is unable to read/write at a sufficient level to provide informed consent. * Subject is unable to make the decision to participate in a clinical investigation on their own or are unable to fully understand all aspects of the investigation that are relevant to the decision to participate. * Subject has presence of medical, social, or psychological conditions that, in the investigator's opinion, could confound the study, limit the subject's ability to participate in the clinical investigation .

Design outcomes

Primary

MeasureTime frameDescription
Successful end-to-end transmission performance metricsThe expected duration of each subject's participation is approximately 30 minutes for an in-clinic visit to complete two transmissions and thereafter an optional at-home transmission (expected duration 10-15 minutes)Successful transmission performance metrics of the AVEIR Remote Care System in approximately 32 subjects who have received an Aveir LP implanted system as part of their standard of care.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026